



ANNUAL REPORT 2024/25


ALL TOGETHER EXTRAORDINARY



– L to R: Aleisha and her Mum Jilksa (diagnosed 2023),
NBCF-funded researchers Professor Paul Beavis
and Dr Joanna Achinger-Kawecka

The National Breast Cancer Foundation (NBCF) acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respects to the past, present and future Traditional Custodians and Elders of this nation and the continuation of cultural, spiritual and educational practices of Aboriginal and Torres Strait Islander peoples.

NBCF ORGANISATIONAL GOVERNANCE AND STRUCTURE



CONTENTS

INTRODUCTION

Message from NBCF Board Chair	2
Message from NBCF CEO	3

RESEARCH

NBCF takes a vital step toward saving lives	4
Collaborative Research Accelerator Grant	5
Research Project Grant recipients	6
A discovery made possible by your support	8

FUNDRAISING

Support goes from strength to strength	11
Celebrating 30 years of impact	11
The Mother’s Day Classic	12
Corporate partners and supporters	16
Celebrating 10 years of the Circle of Giving	18

PEOPLE AND CULTURE

Together for our vision	20
Meet some of our extraordinary team	20

GOVERNANCE

Sources of income	22
Concise financial statements	23
Governance	25

NBCF DONORS

Thank you to all our wonderful supporters	28
---	----

MESSAGE FROM NBCF BOARD CHAIR

This year, the National Breast Cancer Foundation (NBCF) has made an extraordinary leap forward in our vision to achieve Zero Deaths from breast cancer. As Chair, I am proud to reflect on a year defined by bold investment, strategic collaboration and unwavering commitment to impact.

FY2024/25 marks the largest single-year investment in research in NBCF's history. We have committed almost \$28 million to breast cancer research, a milestone that reflects both the generosity of our supporters and the strength of our strategic vision. This includes funding for nine **Research Project Grants** (RPG), and our most ambitious initiative to date – our inaugural **Collaborative Research Accelerator** (CRA) Grant.

The CRA represents a transformative shift in how breast cancer research is conducted in Australia. It is NBCF's first international, multi-institutional grant, designed to solve the most urgent and unsolved challenges in breast cancer. Led by Associate Professor Christine Chaffer at the Garvan Institute, the AllClear program brings together nearly 60 researchers across seven leading institutions and 11 hospitals, including international partners such as Yale and Washington Universities. This program aims to halve breast cancer deaths by stopping recurrence – a challenge that has long eluded researchers and provides so much hope for people affected by breast cancer.

This investment is not only historic in scale but also strategic in design. It reflects our commitment to funding research that is collaborative, ambitious and focused on real-world impact. The CRA is a national endeavour, uniting researchers, clinicians, and communities across metropolitan, regional, and rural Australia. Importantly, people affected by breast cancer are involved at all stages and are at the heart of this research. It is a testament to what can be achieved when we work together toward a common goal.

We also prepared this year to launch our **Pink Sky Grants**, which will support high-risk, high-reward research ideas with the potential to revolutionise how we understand and manage breast cancer. This new funding stream complements our existing portfolio and reflects our belief in backing visionary science that challenges the status quo.

Together, these initiatives form a connected and outcomes-focused research strategy – the *Pink Horizon Research Strategy* – which builds on NBCF's strong legacy while defining a new future.



– Professor Helen Zorbas AO, NBCF Chair

I would like to extend my sincere thanks to the Board of Directors for their steadfast stewardship of NBCF's strategic direction and ambitious vision. Their leadership and governance have been instrumental in enabling this extraordinary year of progress.

I also wish to acknowledge and thank our dedicated CEO, Dr Cleola Anderiesz, the Senior Leadership Team and our amazing staff. Their passion, talent and commitment have successfully driven NBCF forward across all our enterprise endeavours.

As we look ahead, I am filled with optimism. The scale and ambition of our research investment this year signals a new era for NBCF. Philanthropy is critical to our strategic efforts. Together, we are making extraordinary progress toward our vision of Zero Deaths from breast cancer.

Thank you for being part of this journey.

Adjunct Professor Helen Zorbas AO
National Breast Cancer Foundation Chair

MESSAGE FROM NBCF CEO

This has been a truly extraordinary year for NBCF – a year marked by strategic growth, powerful community engagement, and the realisation of bold ambitions in our pursuit of Zero Deaths from breast cancer.

While our research investment reached historic levels, what truly sets FY2024/25 apart is the strength of the community that made it possible. Our donors, fundraisers, corporate partners, ambassadors and volunteers have shown remarkable generosity and belief in our vision. Their support has enabled us to fund transformative research and expand our impact.

Our fundraising efforts were nothing short of inspiring. From the launch of Swim for Breast Cancer, to the continued success of Step Up, GO PINK and the 58 Squat Challenge, thousands of Australians took action to support life-saving research.

The Mother's Day Classic, now in its 27th year, remains one of NBCF's most valued and impactful partnerships. This year, the event reached new heights – raising \$2.13 million for breast cancer research and engaging over 90,000 participants nationwide. We are deeply grateful for our enduring collaboration with the Mother's Day Classic Foundation and proud to stand alongside them in our shared vision.

This spirit of unity and purpose was also reflected in our 30th Anniversary Gala – a celebration of three decades of progress. Proudly presented by David Jones and Estée Lauder Companies, whose generous support – alongside that of other valued partners – underwrote the event and brought together supporters, researchers and corporate partners to honour our collective achievements and reaffirm our commitment to ending deaths from breast cancer.

At the heart of our progress are our extraordinary donors. We are deeply grateful to our individual supporters – those who give monthly, leave a Gift in their Will, or fundraise in memory of loved ones. Their stories of courage, resilience and hope are the heartbeat of NBCF. This year, we also celebrated the profound impact of philanthropy, with major donors and members of our Circle of Giving playing a pivotal role in advancing our mission and enabling bold, life-saving research.

We also extend our sincere thanks to our corporate partners, including our Diamond Partners – David Jones, Estée Lauder Companies, ghd and Professionals Real Estate. Their long-standing support continues to drive awareness, amplify our vision and fuel investment in research that saves lives.



– Dr Cleola Anderiesz, NBCF CEO

Internally, NBCF has continued to evolve. Our team has grown stronger, more connected and more focused than ever. I want to thank our Senior Leadership Team and staff for their tireless dedication and professionalism. Their work behind the scenes has enabled everything we've achieved this year.

Looking ahead, our focus remains clear: to fund the most impactful research, foster innovation, and ensure that every person affected by breast cancer has hope for a better future.

This year has shown us what's possible when generosity meets purpose. With the continued support of our community, we will keep pushing boundaries, and investing in world-class breast cancer research. We are not just working toward change – we are creating it. Together, we are All Together Extraordinary, and we are building a future where Zero Deaths from breast cancer is not just a vision, but a reality.

A handwritten signature in black ink, appearing to read 'Cleola Anderiesz'.

Dr Cleola Anderiesz
National Breast Cancer Foundation CEO


NBCF TAKES A VITAL STEP TOWARD SAVING LIVES

This year marks a significant milestone in NBCF's journey toward our bold vision of **Zero Deaths from breast cancer**.

In late 2023, we launched the *Pink Horizon Research Strategy*, a pioneering five-year plan designed to accelerate progress through targeted, sustained investment in world-class breast cancer research. The strategy builds on 30 years of extraordinary

achievement and reflects our singular focus on ending deaths from breast cancer.

Our funding model is designed to support a connected portfolio of ambitious and transformational research that addresses intractable questions and delivers measurable impact. It is underpinned by a commitment to collaboration, innovation and transparency, guided by four key research objectives:



This year, NBCF activated three grants schemes, marking a major milestone in our research funding evolution.

We awarded nine **Research Project Grants (RPG)** this year, representing a total investment of \$7.9 million in investigator-initiated research projects, with a clear line of sight to Zero Deaths. These grants continue to strengthen Australia's breast cancer research pipeline and support researchers at all career stages.

We also awarded our **first-ever Collaborative Research Accelerator (CRA) Grant**, NBCF's largest single research investment to date. Over five years, the \$25 million CRA is designed to unite leading national and international researchers in a long-term, high-impact collaboration to accelerate progress towards ending deaths from breast cancer. The inaugural CRA was awarded to an exceptional local and international collaboration, led by Associate Professor Christine Chaffer at the Garvan Institute of Medical Research. The ambitious AllClear research program aims to halve breast cancer deaths by tackling one of the most urgent challenges in the field: stopping the recurrence of breast cancer.

In addition, we launched the inaugural **Pink Sky Grant** round, which supports high-risk, high-reward research with the potential to revolutionise how we understand and treat breast cancer. This scheme reflects our commitment to backing novel, paradigm-shifting science. Applications are under review, and we look forward to announcing the first recipients next year.

Together, these three schemes represent a step-change in NBCF's approach, expanding our legacy of investigator-led research to include large-scale collaborative and pioneering research with the potential to transform breast cancer outcomes and save lives.

As we look to the future, we are inspired by the dedication of our researchers, the generosity of our donors and the strength of our community. With continued focus, collaboration and innovation, we are advancing toward a future defined by discovery, impact and hope.

Together, Zero Deaths from breast cancer is possible.

COLLABORATIVE RESEARCH ACCELERATOR GRANT

NBCF has announced a landmark \$25 million investment over five years – the largest in our thirty-year history – awarding its first Collaborative Research Accelerator (CRA) Grant.

As part of NBCF's *Pink Horizon Research Strategy* the CRA Grants will:



Solve critical questions: Tackle the toughest, unanswered questions in breast cancer that hold the key to ending deaths.



Foster collaboration: Build a dynamic research ecosystem that unites Australian and global experts to pursue integrated long-term, high-impact research to transform outcomes and save lives of those affected by breast cancer.



Accelerate progress: Drive breast cancer research forward at a pace and scale that matches the urgency of achieving our vision of Zero Deaths from breast cancer.

COLLABORATIVE PATH TO ZERO DEATHS

The CRA Grant is designed to ignite powerful, long-term collaboration among leading national and international researchers to accelerate progress towards ending deaths from breast cancer.

The AllClear research program is enabled by Garvan's strategic collaboration with St Vincent's Hospital, Sydney and UNSW Sydney, and is a collaboration of nearly 60 researchers across seven leading research institutes and organisations, and 11 hospitals across NSW. AllClear integrates the voices of people with lived experience of breast cancer and ensures diverse representation from metropolitan, regional, rural, and multicultural communities.

Collaborating institutions and organisations:

- National – Breast Cancer Trials
- National – The University of Sydney
- National – University of New South Wales
- National – The University of Newcastle
- National – Australian Catholic University Limited
- International – Yale School of Medicine, USA
- International – Washington University School of Medicine in St Louis, USA

NSW hospital sites:

- St Vincent's Hospital Sydney
- Mater Hospital
- Chris O'Brien Lifehouse
- Westmead Hospital
- Nepean Hospital
- Campbelltown Hospital
- Liverpool Hospital
- Lake Macquarie Private Hospital
- Calvary Mater Newcastle
- Dubbo Hospital
- Wollongong Hospital

– Associate Professor
Christine Chaffer,
NBCF-funded researcher

ALLCLEAR – ACCELERATING RESEARCH, HALVING DEATHS

NBCF's first-ever CRA Grant has been awarded to an exceptional local and international collaboration led by Associate Professor Christine Chaffer at the Garvan Institute of Medical Research, driving forward a pioneering research program called AllClear.

AllClear aims to halve breast cancer deaths by tackling one of the most complex and urgent challenges in the field: How to stop the recurrence of breast cancer.

AllClear program focuses on breast cancer that may have already spread to the bone at the time of diagnosis and aims to:

1. Identify the 'seeds' of relapse early
2. Develop tools to predict who is most at risk of relapse
3. Develop targeted therapies to eliminate these 'seeds' of relapse before they reawaken and cause metastatic breast cancer.



RESEARCH PROJECT GRANT RECIPIENTS

NBCF is proud to have invested \$7.9 million into nine breast cancer research projects that have a clear line of sight to achieve NBCF'S vision of Zero Deaths from breast cancer.



Dr Ajithkumar Vasanthakumar, *Peter MacCallum Cancer Centre*

EXPLORING THE ROLE OF PREGNANCY-INDUCED MAMMARY IMMUNE CELLS IN BREAST CANCER PROTECTION

Dr Ajithkumar Vasanthakumar and his team have discovered that pregnancy triggers the production of specialised immune cells, which seem to offer protection against breast cancer. This study aims to identify the natural signals that induce the production of these breast-associated immune cells with the view to replicate these signals to boost these immune cells and help prevent breast cancer.



Professor Andrew Scott, *Olivia Newton-John Cancer Research Institute*

NOVEL ANTIBODY-BASED DRUGS TO TREAT BREAST CANCERS WITH LIMITED TREATMENT OPTIONS

Human Epidermal Growth Factor Receptor 2 Positive (HER2+) and Triple Negative Breast Cancer (TNBC) can have limited treatment options and poorer overall survival outcomes. Antibody-drug conjugates are targeted therapies that aim to deliver a powerful drug directly to cancer cells. Professor Andrew Scott will assess the effectiveness of novel antibody-drug conjugates on HER2+ and TNBC laboratory models with a view to developing new therapies that are more effective against these tumours while minimising harmful side effects.



Professor Christina Mitchell, *Monash University*

UNDERSTANDING HOW ER+ BREAST CANCERS EVADE THE IMMUNE SYSTEM

Immunotherapies have revolutionised the treatment of certain cancers. However, Estrogen Receptor Positive (ER+) breast cancer can evade the immune system and immunotherapies can be ineffective. Professor Christina Mitchell aims to investigate how relapsed ER+ breast cancer evades immune surveillance, with the goal of revealing strategies to reactivate the immune system to improve outcomes for people with relapsed ER+ disease.



Professor Geoff Lindeman, *WEHI*

TOWARDS MORE EFFECTIVE THERAPIES FOR PEOPLE WITH RELAPSED BREAST CANCER

Estrogen Receptor Positive (ER+) breast cancer is the most common subtype of breast cancer accounting for the greatest number of relapses and breast cancer deaths. Professor Geoff Lindeman aims to test new potent inhibitors of BCL2, a pro-survival protein, and develop optimal strategies to target this protein for people with relapsed ER+ breast cancer to inform the development of novel treatment combinations.



Dr Joanna Achinger-Kawecka, *University of Adelaide*

HARNESSING P53 TO TARGET CDK4/6 INHIBITORS RESISTANT BREAST CANCER

Funded by the Mother's Day Classic Foundation

About 30% of Estrogen Receptor Positive (ER+) breast cancer cases progress to metastatic disease due to resistance to CDK4/6i, the standard of care treatment, with no clear second-line strategy currently available. Dr Joanna Achinger-Kawecka will test new combination therapies, offering potential treatment options for people who relapse on CDK4/6i therapy.



Associate Professor Kara Britt, *Peter MacCallum Cancer Centre*

INVESTIGATING WOUND HEALING IN THE BREAST AS A NEW BREAST CANCER PREVENTIVE THERAPY

Co-funded by Mother's Day Classic Foundation and National Breast Cancer Foundation

Associate Professor Kara Britt has found that lower levels of a specific protein are seen in the breast tissue of women who have never had children. Lower levels of this protein are detected in people with breast cancer who have poorer outcomes. This study will investigate how this protein is blocking breast cancer growth and whether drugs that target it can elevate its level and be effective in preventing breast cancer.



Professor Paul Beavis, *Peter MacCallum Cancer Centre*

BOOSTING IMMUNE THERAPY FOR BREAST CANCER BY FACILITATING MOVEMENT OF IMMUNE CELLS INTO THE TUMOUR

Immunotherapy has shown promise in treating many people with Triple Negative Breast Cancer (TNBC), but not all experience positive results. Professor Paul Beavis is focused on developing new methods to improve the movement of immune cells to tumours, aiming to improve the efficacy of currently approved immunotherapies for people with TNBC.



Professor Rik Thompson, *Queensland University of Technology*

NEW TREATMENT OPTIONS FOR TNBC TARGETING CELL PLASTICITY

Triple Negative Breast Cancer (TNBC) has limited treatment options and poor survival outcomes. Professor Rik Thompson and his team aim to uncover the factors that enable cells to switch between different cell states, increasing their metastatic potential and resistance to therapy, with the goal of targeting these factors to hinder tumour progression in preclinical models of TNBC.



Professor Scott Mueller, *University of Melbourne*

REJUVENATING THE LYMPH NODES TO TREAT BREAST CANCER METASTASIS

Funded by the Mother's Day Classic Foundation

Cancer that spreads to the lymph nodes, often the first site of metastasis, can hinder the effectiveness of immunotherapy responses. Professor Scott Mueller and colleagues aim to use state-of-the-art laboratory models of metastasis and samples from people with breast cancer. This will enable them to identify novel cellular pathways and molecules that can restore the lymph nodes' anti-tumour immune function, which is compromised by cancer cell invasion, to enhance the effectiveness of immunotherapy.

A DISCOVERY MADE POSSIBLE BY YOUR SUPPORT

Smarter CAR T cells: A safer, more effective way to target breast cancer

Thanks to funding from NBCF, researchers at the Peter MacCallum Cancer Centre have made a remarkable breakthrough. Led by Professor Paul Beavis and Professor Phil Darcy, these brilliant minds have developed a powerful new way to treat breast cancer with Chimeric Antigen Receptor (CAR) T-cell therapy, a cutting-edge type of immunotherapy.

It's not every day that a researcher finds themselves being published in *Nature*, one of the world's most reputable scientific journals, which only accepts the very best research.


Professor Beavis, Professor Darcy and their team's latest discovery of a new approach to deliver CAR T-cell therapy could make immunotherapies

safer and more effective for metastatic and hard-to-treat breast cancers, and other solid tumours. Known as a 'living drug', CAR T-cell therapy is a treatment where a person's own immune cells (T cells) are collected and re-engineered to **enhance their ability to detect and kill cancer cells**. CAR T-cell therapy has been effective at treating blood cancers, with variable results in solid tumours like breast cancer.

Using a cutting-edge gene editing tool called CRISPR, the researchers have developed smarter 'armoured' immune cells, called Precision Guided Munition (PGM) CAR T-cells, that can better target solid tumours like breast cancer. This targeted approach reprograms T cells, so they only deliver special proteins called cytokines to boost the immune response at the tumour site. This avoids causing damage to healthy tissue and reduces harmful side effects.

"We are deeply grateful and would like to acknowledge the continued support of our work from NBCF for developing new approaches for enhancing CAR T-cell therapies. In particular, the funding contributed significantly to the development and evaluation of our CRISPR/HDR editing technology for tumour-specific expression of genes that enabled the eradication of a broad range of tumour types in preclinical models, including breast cancer. This is a key step prior to testing this novel approach in people living with breast cancer."

– Professor Phil Darcy, Co-Lead



Rewriting the code of life: What is CRISPR and why is it important?

CRISPR, short for Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene editing tool that is adapted from a natural process found in the immune defence system of bacteria. This brilliant technology makes it possible for scientists to rewrite the code of life itself.

CRISPR enables scientists to 'cut and paste' sections of DNA with a precise pair of 'genetic scissors' to permanently add, remove or alter the genes of almost any living cell or organism, including people.

Compared with other gene editing technologies, CRISPR is the most efficient way to modify genetic material – and treat diseases. Since its discovery by Noble Laureates Dr Emmanuelle Charpentier and Dr Jennifer Doudna in 2012, CRISPR has been widely adopted across scientific disciplines, accelerating our understanding of cancer biology and paving the way for new, targeted treatments for the disease.

THE FIRST AUSTRALIAN TO RECEIVE A LLOYD J. OLD STAR AWARD

In 2024, Professor Paul Beavis was named a Lloyd J. Old STAR (Scientists Taking Risks), becoming the first Australian-based researcher to be awarded the prestigious grant by the U.S. Cancer Research Institute (CRI).

This award, valued at US\$1.25 million, recognises the incredible potential of Professor Beavis' contributions to the immunotherapy field, with over 13,000 citations and 80 publications to his name. It is a well-earned reflection of his leadership in pioneering innovative ways to make CAR T-cell therapy safer and more effective against breast and other solid tumours.

The researchers were able to achieve this by harnessing the body's natural gene 'on switches' called promoters to support the armoured T cells' release of the cytokines only where they're needed, creating a **precise and potent immune response against the cancer**.

In nearly all lab models of breast, colon and ovarian cancer, these armoured T cells were able to achieve phenomenal results by successfully treating the tumours and significantly **reducing side effects**.

With such promising results, Professor Beavis, Professor Darcy and their team are looking to undertake **the first clinical trial** of PGM CAR T-cell therapy in solid tumours, including breast cancer. This brings their research closer to becoming a real-world treatment.

This research is a vital step towards NBCF's vision of Zero Deaths from breast cancer. **Thanks to the amazing support of the NBCF community, these dedicated researchers can continue their pioneering research, which has the potential to improve the survival of people living with metastatic and hard-to-treat breast cancers** like Triple Negative Breast Cancer (TNBC).



“I am deeply grateful to NBCF and their supporters for their generous support of our CAR T-cell research. Your commitment to advancing breast cancer research brings hope to countless individuals and families affected by this disease. With your support, we have developed an exciting new therapy that we hope can change lives in the future.”

– Professor Paul Beavis, NBCF-funded researcher



Elaine Henry OAM

2025 ELAINE HENRY FELLOWSHIP RECIPIENT

The Elaine Henry Fellowship was established in 2020 and is awarded to a rising star who demonstrates great potential to be a future leader in breast cancer research. It pays tribute to Elaine Henry OAM, who was Chair of our Board for nine years and an integral member since our founding. The Fellowship provides \$20,000 in additional funding for an NBCF Research Project Grant and is funded by NBCF.

Dr Joanna Achinger-Kawecka, *The University of Adelaide*

HARNESSING P53 TO TARGET CDK4/6 INHIBITORS RESISTANT BREAST CANCER

Dr Joanna Achinger-Kawecka has been awarded the 2025 Elaine Henry Fellowship to advance her career as a future leader in breast cancer research. Dr Achinger-Kawecka's scientific career has been focused on investigating the three-dimensional epigenome in cancer: the way that DNA is folded and organised inside each cell. This is important because any changes in the organisation of DNA can drive tumour progression and treatment resistance in cancer. For more information, see page 7.

“With the support of the Elaine Henry Fellowship, I aspire to make substantial contributions to the development of novel therapeutic approaches, the identification of predictive biomarkers, and the translation of research findings into improved clinical outcomes for people living with breast cancer.” – Dr Achinger-Kawecka



Mavis Robertson

2025 MAVIS ROBERTSON FELLOWSHIP RECIPIENT

The Mavis Robertson Fellowship was established in 2011 and is awarded to a female applicant considered by NBCF to exhibit the greatest promise as a leader in breast cancer research. The Fellowship provides \$10,000 in additional funding for an NBCF Research Project Grant and is funded by the Mother's Day Classic Foundation.

Dr Laura Marruecos Aylagas, *WEHI*


TOWARDS MORE EFFECTIVE THERAPIES FOR PEOPLE WITH RELAPSED BREAST CANCER

Funded by the Mother's Day Classic Foundation

Dr Laura Marruecos Aylagas has been awarded the 2025 Mavis Robertson Fellowship. Dr Marruecos Aylagas is a scientist who is passionate about understanding the process behind cancer development. At the heart of her scientific interests is the quest to uncover how normal cells undergo transformation into tumorigenic states. She is a Co-Investigator in Professor Geoff Lindeman's NBCF Research Project Grant – for more information, see page 6.

Under Professor Lindeman's mentorship, Dr Marruecos Aylagas will use cutting-edge technology to follow individual breast cancer cells in preclinical breast cancer models. This will help spot the cells that manage to survive treatment and understand why they resist it. The same technology also makes it possible to find patterns in how genes are switched on or off, which will give clues about how breast cancer grows and behaves.

“This fellowship will be a crucial milestone in my career, paving the way for my development into an independent breast cancer researcher in Australia. I am committed to working towards better outcomes for people living with breast cancer and aim to make a substantial contribution to this field.” – Dr Marruecos Aylagas



SUPPORT FOR LIFE-SAVING BREAST CANCER RESEARCH GOES FROM STRENGTH TO STRENGTH

This year has been a remarkable one for fundraising, driven by the incredible generosity of our corporate partners, donors and community supporters. Together, we've achieved significant milestones that reflect the strength and unity of our vision.

Some of the highlights include:

- All our major community fundraising campaigns reached new levels of support, engaging more supporters that walked, ran, squatted and turned pink to support breast cancer research.
- We launched a new initiative, the Swim for Breast Cancer Challenge, expanding our reach and engagement.
- For the second year running, we were proud to be the official charity partner of the City of Sydney's New Year's Eve celebrations.
- Our 30th anniversary Gala event was a resounding success thanks to the extraordinary contributions of our sponsors, supporters and donors.

Fundraising continues to be the driving force behind our progress toward a future free from breast cancer deaths. Every contribution – whether through events, community fundraising campaigns, corporate partnerships or individual giving – helps accelerate vital research and brings us closer to life-saving breakthroughs.

We are deeply grateful to every individual and business who has stood with us in support of breast cancer research. Your belief in our vision continues to inspire and drive meaningful change.

\$3.48M from corporate partners who support us through cause-related marketing, philanthropic donations, workplace giving, fundraising and pro-bono services.

\$14.35M from community fundraisers who come together with friends, family and their communities to raise vital funds.

\$31.5M from individual donors who support us through donations or monthly giving.

\$1.78M from donors who leave a generous gift in their Will.

\$3.23M from philanthropy, trusts and foundations, including the Mother's Day Classic Foundation and other generous donors who invest in breast cancer research.

CELEBRATING 30 YEARS OF IMPACT

In April 2024, NBCF marked a momentous milestone: 30 years of unwavering commitment to breast cancer research with the 30 Years Extraordinary Gala. This unforgettable evening, fully underwritten by our generous partners, brought together our community of supporters, researchers, ambassadors and partners to reflect on three decades of progress and to look ahead with renewed purpose.

Held in The Fullerton Grand Ballroom, Sydney, the Gala was a celebration of recognition and hope for a future of Zero Deaths from breast cancer. We were honoured to welcome our founding partners, David Jones and The Estée Lauder Companies, as Presenting Partners for the event. Their enduring support since NBCF's inception has been instrumental in driving our vision forward. Their presence at the Gala was a powerful reminder of the impact that long-term collaboration can achieve.

As we celebrated 30 years of progress, we also reignited our shared commitment to achieving Zero Deaths from breast cancer. A heartfelt thank you to our Gala Committee, Rebecca Caratti, Fiona Carns, Ciara Griffiths, Lucie McGeoch, Helen Mantzsis and Pat Stragalinos.



THE MOTHER'S DAY CLASSIC

A POWERFUL PARTNERSHIP DRIVING CHANGE

The Mother's Day Classic, founded by Women in Super, remains one of NBCF's most valued and impactful partnerships, bringing communities together across Australia to fund life-saving breast and ovarian cancer research. In 2025, the event reached new heights, showcasing the strength and dedication of supporters nationwide. Donating an incredible \$2.13 million to support extraordinary breast cancer research projects and a further \$1.37 million to ovarian cancer research, with a total of \$3.5 million donated overall.

This year, the Mother's Day Classic was held in over 80 locations, including six new ones, expanding its reach to even more communities. The event attracted 90,000 participants, reflecting the enduring commitment of people in Australia to world-class research. Notably, over 27,000 participants joined local events – a 24% increase from 2024, highlighting growing enthusiasm for grassroots involvement.

The 2025 event also saw a 15% increase in runners, underscoring the event's evolution into a more dynamic and inclusive experience for people of all fitness levels. The success of the event was made possible by 1,500 volunteers who generously gave their time and energy to ensure every event ran smoothly.

NBCF is proud to stand alongside the Mother's Day Classic Foundation and the Ovarian Cancer Research Foundation in this powerful partnership. Together, we are not only raising vital funds for breast and ovarian cancer research, but also fostering a nationwide movement of hope, resilience and community spirit.

“The true impact of the Mother's Day Classic lies in the community that brings it to life. Together, our participants, volunteers, donors and supporters have created something deeply meaningful – turning one of the most emotional days of the year into a shared experience of strength, connection and hope. This event is more than a fun run and walk. It's a community of support and a commitment to life-changing research that will benefit generations to come.”

– Zara Lawless, Mother's Day Classic Foundation CEO



“Every step we take together moves us closer to NBCF's vision of Zero Deaths. A sincere thank you to everyone who makes this incredible event possible.”

– Dr Cleola Anderiesz, NBCF CEO







LEANA STEPS UP WITH STRENGTH

Step Up to Breast Cancer

Leana joined our Step Up to Breast Cancer challenge while undergoing treatment for Stage IIIB (3B) breast cancer. Diagnosed on her 42nd birthday, she faced chemotherapy, a double mastectomy, lymph node surgery and radiation. Despite the toll, Leana turned her experience into a mission to help others. In total she raised \$2,244 for breast cancer research through the challenge. Her courage and determination inspired support from her community, colleagues and friends. Leana's fundraising journey reflects her strength and unwavering commitment to helping achieve NBCF's vision of Zero Deaths from breast cancer.



PARKY GOES PINK

Chris' mission to fund breast cancer research

Chris began fundraising in 2024, driven by the loss of his partner to cancer in May 2023. After trialling various treatments, including breast cancer chemo that extended their life from three months to four years Chris became passionate about funding research. He launched the Parky Goes Pink event – a 12-hour sailing marathon, pink luncheon, and live music with auctions. In its first year, the event raised \$12,392, and in 2025, it soared to \$20,230. For Chris, it's more than fundraising: It's a tribute and a commitment to saving lives through research.



TEAM BLUE TURNS PINK

A decade of GO PINK

In 2015, Sam's wife Sarah was diagnosed with breast cancer and underwent a double mastectomy. Sam wanted to honour her journey and raise funds for NBCF. He asked his manager at BlueScope Steel to wear a pink shirt for GO PINK and with their unwavering support, his colleagues also joined in. In 2017, 'Team Blue Turns Pink' was born. The team has returned every year since, proudly marking their 10th GO PINK anniversary in 2025 and raising over \$50,000 to support world-class breast cancer research.



THE THREE PINK LADIES

Pink Ribbon Breakfast

Anna, Danielle and Kylie, known as the Three Pink Ladies, are passionate breast cancer advocates. Inspired by loved ones affected by the disease, they host their signature Sparkling Pink High Tea each October for NBCF's Pink Ribbon Breakfast. Their event brings the community together to raise vital funds for breast cancer research. With unwavering commitment and heartfelt purpose, the Three Pink Ladies have raised over \$40,000, proving that a shared mission and strong community can make a powerful impact.



MAKING WAVES

Swim For Breast Cancer's incredible first year

Max joined our Swim for Breast Cancer challenge in support of his mum, Marie, who was diagnosed in early 2024. Inspired by her strength throughout treatment, Max turned his love of swimming into a powerful fundraising effort, raising an incredible \$22,357 for breast cancer research. With support from friends, family and his swim club, Max found purpose in every lap. His dedication reflects a heartfelt desire to help others detect breast cancer earlier and save lives through research. Max's journey is a moving tribute to his mum, and a shining example of the impact one person can make.



A DECADE OF DEDICATION

Local footballer honours Mum

Harry was just 12 when his mum Cathy was diagnosed with breast cancer. After more than five years of treatment, she passed away in 2015 on Harry's first day of Year 12 and his brother's 16th birthday. Football became Harry's outlet, and soon after, he launched the Wattle Park Amateurs Ladies Luncheon. Over the past decade, he's raised more than \$200,000 for NBCF. For Harry, the event is more than a fundraiser: It's a heartfelt tribute to Cathy and a mission to help fund life-saving breast cancer research.



COURTNEY'S MOTIVATION

58 Squat Challenge

Diagnosed with aggressive breast cancer, Courtney faced chemotherapy and recovery from a mastectomy with incredible strength. She took on the 58 Squat Challenge, raising \$13,909 for NBCF. The challenge's symbolism, 58 squats for the 58 Australians diagnosed daily, kept her motivated throughout treatment. With a family history of breast cancer and the emotional toll of sharing her diagnosis while navigating motherhood, Courtney's authenticity and determination inspired her community. Her fundraising was a powerful act of hope and advocacy, supporting life-saving research and embodying NBCF's vision to achieve Zero Deaths from breast cancer.



RACE FOR RESEARCH

Noosa Triathlon

Jennifer was diagnosed with Invasive Lobular Breast Cancer in November 2022 and underwent a double mastectomy soon after. Almost a year later, she completed the Noosa Tri for Team NBCF. Unstoppable, Jennifer returned in 2024 to take on the Olympic distance again, raising \$2,475 for vital breast cancer research. Training helped her heal physically and emotionally, and fundraising was her way of giving back in appreciation of the world-class research and care that supported her. Jennifer's story is a powerful example of strength, resilience, and how committed our supporters are helping us end deaths from breast cancer.

CORPORATE PARTNERS AND SUPPORTERS

At NBCF, we are proud to partner with leading Australian companies whose commitment to our vision goes beyond financial support. Our corporate partners play a vital role in advancing life-saving breast cancer research through support embedded in their products and services, team-driven fundraising initiatives, and employee payroll giving programs.

Each partnership is unique, built on shared values and sustained engagement, and a collective drive toward achieving our vision of Zero Deaths from breast cancer. These collaborations not only raise essential funds, but also amplify awareness across diverse communities.

We are deeply grateful to all our partners and supporters. In particular, we acknowledge our **Pink Diamond Partner**, Mother's Day Classic Foundation, and our **Diamond Partners**: David Jones, Estée Lauder Companies, ghd and Professionals Real Estate.

We also warmly welcome the new Partners and Supporters who join us in bringing us closer to a future free from breast cancer deaths. Partners: Green Valley Grains and Vetta. Supporters: Aquaboss, iTechworld and KickOn Group.



A MILESTONE 30 YEARS FOR NBCF, DAVID JONES AND ESTÉE LAUDER COMPANIES

David Jones and Estée Lauder Companies celebrated their enduring 30-year commitment to breast cancer research by becoming the Presenting Partners of our 30th Anniversary Gala. Their incredible support has spanned three decades and made an enduring impact on advancing breast cancer research and bringing hope to thousands impacted every year.

David Jones support spans a range of fundraising initiatives held at important times, including International Women's Day, Mother's Day and Breast Cancer Awareness Month each year. Proceeds from select bras sold during October, dedicated shopping events, and other annual events such as Pink Ribbon Breakfast, high tea celebrations and staff participation in the Mother's Day Classic have contributed to their fundraising efforts.

Estée Lauder Companies has been a global leader in raising awareness, driving education and funding research to help end breast cancer. Since Evelyn H. Lauder launched the Breast Cancer Campaign in 1992, their commitment has united communities worldwide. In this milestone year, their continued partnership with NBCF reflects a shared vision for a future where no one dies from breast cancer.





PAMELA LEE – THE WOMEN CHAMPIONING WORKPLACE GIVING AT CA ANZ

Pamela Lee FCA has led Chartered Accountants Australia & New Zealand's (CA ANZ) partnership with NBCF since 2010 when Pamela recognised the importance of aligning the organisation with a meaningful cause. Having her own personal lived experience with breast cancer, Pamela is passionate about the critical importance of breast cancer research.

Her leadership has supported nine charity partners, including NBCF, through payroll giving and annual fundraising events both internally and across their member network. One of the first initiatives she led was the 'Everybody Counts' workplace giving program, fostering a strong culture of philanthropy since 2006. The program has grown from strength to strength raising over \$360,000 for NBCF with over 100 employees participating.

Pamela also coordinates their involvement in the Mother's Day Classic, where staff-raised funds are matched by CA ANZ, a great incentive to drive participation. In 2024, Pamela supported a membership renewal initiative prompting members to donate \$9, symbolising the nine people in Australia who die each day from breast cancer. Pamela's efforts earned her the Workplace Giving Australia Champion Award.



HONOURING 20 YEARS OF PARTNERSHIP WITH GHD

This year marks an extraordinary 20 years of partnership between ghd and NBCF, united by a shared vision of Zero Deaths from breast cancer.

Since launching their iconic Pink Collection, ghd has raised over AU\$4.8 million in Australia and more than US\$24 million globally. By donating \$20 from every pink styling tool sold, ghd funds essential breast cancer research and sparks conversations among their customers and community about the importance of early detection and being breast aware.

ghd's impact goes far beyond styling tools. From salon champions and pink muses to heartfelt activations to engage the wider community, ghd's dedication weaves purpose into daily routines, transforming everyday beauty moments into meaningful contributions that fund vital breast cancer research.



ME BANK CELEBRATES 14 YEARS OF SUPPORT

For over a decade, ME Bank has stood alongside NBCF, united by the shared vision of Zero Deaths from breast cancer.

Through their iconic Pink SpendME debit card, ME empowers everyday Australians to contribute to life-saving research with every digital wallet tap. This simple yet powerful initiative has raised over \$2 million over the partnership.

ME's commitment goes beyond financial support. By amplifying awareness and fostering community engagement, they inspire both customers and their people to actively support NBCF's vision. Together, we're not just banking on change – we're investing in a future where no life is lost to breast cancer.

CELEBRATING 10 YEARS OF THE CIRCLE OF GIVING

A FAMILY LEGACY OF IMPACT

As the Circle of Giving marks its 10th anniversary, founding member Sanchia Brahimi and her father, Charles Curran AC, reflect on their family's enduring commitment to philanthropy and improving health outcomes.

Philanthropic values run deep in the Curran family. Charles' dedication was shaped early by his parents, who instilled in him the importance of making a lifelong, positive impact on society. Charles has long been a pillar of philanthropic leadership in Australia having been involved in establishing the St Vincent's Curran Foundation, a public ancillary foundation that has grown from modest beginnings into a transformative force, now managing over \$100 million in endowments with the mission of advancing healthcare.


But the Curran family's story is not just one of leadership – it's one of compassion and connection. Charles' wife, Eva Curran, and daughter, Sanchia, were both deeply moved by the experiences of close friends facing breast cancer. Recognising the urgent need for greater awareness and research, they became founding members of NBCF's Circle of Giving, an initiative launched by Sanchia and Board Director Deeta Colvin to bring together individuals committed to making a lasting impact on breast cancer outcomes.

Since its inception, the Circle of Giving has steadily grown, funding innovative world-class breast cancer research projects and building a strong, engaged philanthropy donor community. Sanchia's commitment to driving awareness and support has remained unwavering over the past decade, and with Eva's passing, Charles now continues her legacy as a proud member of the Circle.

Together, Charles and Sanchia exemplify the power of multi-generational philanthropy – leading by example, nurturing younger generations and ensuring that their family legacy continues to evolve. Their story is a powerful reminder of how generosity can be woven into the fabric of family life, creating ripples of impact across communities.

By sharing their journey, the family hopes to inspire others to reflect on their own giving. Their ongoing commitment to a critical health issue that touches countless lives shows how philanthropy, passed down through generations, can create lasting and meaningful change.

NBCF extends heartfelt thanks to all past and current Circle of Giving members across Sydney, Melbourne, Gold Coast and Brisbane, whose generosity continues to drive progress in breast cancer research and awareness.



– Sanchia Brahimi

– Charles Curran AC

GIFTS IN WILL

NBCF is honoured by the generosity of people who choose to add a Gift in their Will, helping fund life-saving research aimed at creating a future where no one dies from breast cancer.

After caring for their loved ones, many supporters choose to make a profound impact by including causes close to their hearts – reflecting their values and the meaningful legacy they wish to leave behind.



Remembering Claire

NBCF supporter Claire was a registered nurse and passionate advocate for breast cancer research. Claire sadly passed away in January from extensive liver metastases, five years after her initial diagnosis. Deeply committed to improving treatments for metastatic breast cancer, she hoped that future research would unlock breakthroughs in understanding cell mutation and drug resistance.

By including a Gift in her Will to NBCF, Claire's commitment to advancing breast cancer research lives on. Her legacy is helping drive progress today – and will continue to do so for years to come.

APPEAL DONORS

We are thankful to our supporters who donated to NBCF for the first time, becoming a part of our breast cancer community, and incredibly grateful for the donors who continue to support us year after year. Your donation helps NBCF to continue to fund life-saving breast cancer research.

The end of the financial year is always the busiest time of year, with many of our donors preferring to donate during this time.

This year, as part of our Tax Appeal, we shared the story of Ashliegh, whose mother sadly passed away from breast cancer. Ashliegh's story inspired an incredible response from over 9,000 donors who collectively raised \$1.26 million for breast cancer research.

Thank you to all the donors who contributed to this and we would also like to extend our heartfelt gratitude to the 22,783 individual donors who supported us throughout the year to continue to work towards our shared vision of Zero Deaths from breast cancer.

You have made and continue to make an incredible impact. We couldn't do what we do without the incredible support of people like you!

REGULAR GIVING

Our sincere thanks to all our Pink Ribbon Partners, a group of generous donors who support NBCF with a gift every month. Your loyalty and commitment towards our shared vision of Zero Deaths from breast cancer has been instrumental in the progress we have made and is critical so that we can continue to break new ground.

Your generosity and belief in research have given hope to countless Australians affected by breast cancer.

We are truly humbled by your dedication, which will ultimately allow so many people in Australia who are going through breast cancer to live longer lives.

From all of us at NBCF, thank you for your ongoing support and commitment towards ending deaths from breast cancer. We truly could not do it without you.

TOGETHER FOR OUR VISION

At NBCF, our people are the heartbeat of everything we do. United by purpose and powered by expertise, our team brings together professionals across research, fundraising, digital, marketing, finance, human resources, and more – each contributing their unique skills to help achieve our vision of Zero Deaths from breast cancer.

This year, we've continued to nurture a culture that values collaboration, compassion and inclusion. Our people are not only experts in their field; they are champions of innovation and integrity, grounded in our values and inspired by the impact of their work. In partnership with our Board, researchers and community ambassadors, our team remains focused on shaping a future where no life is lost to breast cancer.

MEET SOME OF OUR EXTRAORDINARY TEAM



TULASI TIPPA, DATA AND INSIGHTS EXECUTIVE

As a Data & Insights Executive at NBCF, I support fundraising through data management, campaign analysis and reporting. I work closely with teams to streamline processes, maintain our data warehouse and deliver insights that help drive informed decisions.

My journey with NBCF began as a volunteer after migrating to Australia. Within six months, I was offered a permanent role, an opportunity I'll always treasure. One of my proudest moments was using Power BI to support a major fundraising contract negotiation during the early days of tool adoption. Helping implement our centralised data warehouse has also been a major achievement. It's improved our reporting and automation, and I'm proud to have led its setup and adoption.

What I love most is the supportive, collaborative culture. I've grown personally and professionally, especially in building confidence as an introvert. I'm excited to contribute to NBCF's digital strategy and our shared vision of Zero Deaths from breast cancer. Working at NBCF is more than a job – it's a chance to give back. For anyone considering the not-for-profit sector, join us and experience the joy of making a difference.



BELLA WONG, DIGITAL MARKETING SPECIALIST

As Digital Marketing Specialist in NBCF's Martech team, I focus on creating innovative digital initiatives that enhance user experience, optimise platform performance and support organisational growth. My day-to-day includes managing email campaigns, updating website content, improving SEO, and analysing site performance to uncover growth opportunities.

NBCF holds a special place in my heart. My mum was diagnosed with breast cancer in 2015 and is now in remission. That personal connection drives my passion for the work we do. One of my most memorable experiences was NBCF's 30th anniversary brand shoot, where I met our inspiring ambassadors, fundraisers and researchers. Hearing their stories reminded me why our vision matters and gave me a deeper sense of purpose.

I'm proud of my transition from Digital Communications and Engagement Manager to my current role, which challenged me to grow and step outside my comfort zone. What brings me joy is working with a supportive, fun team and feeling the love from our community and partners. Looking ahead, I'm excited to keep learning and contributing to NBCF's evolution. For anyone considering the not-for-profit sector, do it! It's full of passionate people making a real difference, and the energy is truly contagious.



SARAH-JANE MONAHAS, HEAD OF INDIVIDUAL GIVING & SUPPORTER ENGAGEMENT

As Head of Individual Giving and Supporter Engagement at NBCF, I lead a passionate team dedicated to raising vital funds for breast cancer research and connecting donors with the impact of their support. Each day involves monitoring fundraising performance, reviewing ambassador stories, supporting donor communications, and ensuring our work is high-quality, compliant and compassionate.


I joined NBCF because breast cancer has touched people close to me, and it's incredibly fulfilling to contribute to a cause that strives for Zero Deaths from breast cancer. One of my most memorable experiences is hearing directly from our funded researchers: Their brilliance and ability to explain complex science is truly inspiring.

A proud career moment was being appointed to the Board of the Public Fundraising Regulatory Association (PFRA). I'm passionate about maintaining high standards in fundraising, and this role allows me to support best practice across the sector.

What brings me joy is working with the kindest, most committed people, both our team and our donors. Looking ahead, I'm excited to keep learning, especially as donor engagement evolves in the digital space. My role allows me to make a meaningful difference, and that's what I love most.

SOURCES OF INCOME

In FY2024/25 there was a 9.2% increase YOY in fundraising revenue due to strong growth in the individual giving, community fundraising and corporate partnerships channels.



L to R: Angus, NBCF Fundraiser,
Michaela and her Mum, Elizabeth
(diagnosed 2023)

CONCISE FINANCIAL STATEMENTS

The following information is based on the audited financial statements of NBCF and should be read in conjunction with those financial statements, a copy of which can be found at nbcf.org.au

STATEMENT OF COMPREHENSIVE INCOME

for the year ended 30 June 2025

	2025 \$'000	2024 \$'000
Revenue from fundraising activities	54,349	49,768
Donations in kind income	679	568
Other income	2,272	6,897
Revenue from continuing operations	57,300	57,233
Donations in kind expense	(679)	(568)
Direct cost of fundraising	(20,532)	(19,630)
Depreciation and amortisation	(650)	(631)
Employee benefits expense	(8,116)	(7,020)
Rent	(22)	(51)
Other operating expenses	(2,355)	(2,699)
Loss on disposal of assets	-	-
Net loss on financial assets	-	-
Surplus before grant expense and income tax	24,946	26,634
Research grants awarded	(27,979)	(13,587)
Research grants relinquished	52	15
Revaluation of future research grants provision	681	154
Surplus/(Deficit) before income tax	(2,300)	13,216
Income tax expense	-	-
Surplus/(Deficit) for the year	(2,300)	13,216
Other comprehensive income for the year, net of tax	-	-
Total comprehensive income/(deficit) for the year	(2,300)	13,216

The above statement of comprehensive income should be read in conjunction with the accompanying notes in the annual financial report.

In FY2024/25, the first year of the *Pink Horizon Research Strategy*, NBCF more than doubled its investment in breast cancer research compared to the prior year. This significant uplift was driven by strong revenue growth and was made possible through the generosity of our community and the effectiveness of our engagement strategies.

Regarding expenditure, NBCF maintained disciplined cost management while scaling operations to support the expanded research agenda. Employee benefits expense increased, reflecting our commitment to building talent and capacity to deliver on strategic priorities. Direct fundraising costs rose modestly maintaining a strong return on investment, and other operating expenses decreased, demonstrating continued efficiency in core operations.

CONCISE FINANCIAL STATEMENTS (CONTINUED)

STATEMENT OF FINANCIAL POSITION

for the year ended 30 June 2025

	2025 \$'000	2024 \$'000
ASSETS		
Current assets		
Cash and cash equivalents	20,049	16,775
Trade and other receivables	2,009	3,951
Financial assets	62,263	56,734
Total current assets	84,321	77,460
Non-current assets		
Financial assets	309	309
Investment in associates	-	-
Property, plant and equipment	212	300
Right of use assets	657	1,152
Total non-current assets	1,178	1,761
Total assets	85,499	79,221
LIABILITIES		
Current liabilities		
Trade and other payables	1,219	2,338
Lease liabilities	554	731
Provisions	16,976	15,720
Total current liabilities	18,749	18,789
Non-current liabilities		
Lease liabilities	186	510
Provisions	20,064	11,122
Total non-current liabilities	20,250	11,632
Total liabilities	38,999	30,421
Net assets	46,500	48,800
EQUITY		
Accumulated funds	46,500	48,800
Total equity	46,500	48,800

STATEMENT OF CASH FLOWS

for the year ended 30 June 2025

	2025 \$'000	2024 \$'000
Cash flows from operating activities		
Receipts from grants, donations and fundraising activities	54,756	50,146
Payments for research grants, suppliers and employees	(49,652)	(42,166)
Net cash (outflow)/inflow from operating activities	5,104	7,980
Cash flows from investing activities		
Payments for property, plant and equipment	(54)	(35)
Proceeds from short-term deposits and investments	56,463	10,126
Payments for short-term deposits and investments	(60,436)	(9,724)
Bank interest income received	213	90
Investment income received	2,546	1,329
Net cash (outflow)/inflow from investing activities	(1,268)	1,786
Cash flows from financing activities		
Payment of lease liabilities	(562)	(514)
Net cash (outflow)/inflow from financing activities	(562)	(514)
Net increase/(decrease) in cash	3,274	9,252
Opening cash	16,775	7,523
Closing cash end of year	20,049	16,775

The above statements of financial position and cash flows should be read in conjunction with the accompanying notes in the annual financial report.

GOVERNANCE

The Board and Management are committed to NBCF's vision of Zero Deaths from breast cancer. NBCF operates within a sound corporate governance framework, ensuring compliance with the Australian Charities and Not-For-Profit Commission's (ACNC) Governance Standards. The Board has established appropriate committees to ensure it adequately discharges responsibilities and duties. The committees are Audit, Risk, and Investment; and Remuneration and Nominations Committee. The Foundation also has a Research Advisory Committee, and a Consumer Advisory Panel.



Adjunct Professor Helen Zorbas AO MBBS FASBP MAICD

Board member for 5 years

Adjunct Professor Helen Zorbas AO stepped down from her role as CEO of Cancer Australia in 2019 after ten years leading initiatives in evidence-based cancer practice, policy and research. Prior to this, she was CEO of the National Breast Cancer Centre (NBCC), which then became the National Breast and Ovarian Cancer Centre (NBOCC). In addition to her extensive clinical experience across both the public and private health sector, Helen has chaired government Reviews and committees, represented Australia in international cancer initiatives, held NHMRC principle committee appointments and positions in leading cancer and health organisations. She has also served as a Director and Chair of the Board of Cancer Institute NSW and Director of NBOCC.

Professor Zorbas currently holds non-executive Director positions as Chair of National Breast Cancer Foundation, Director on the Board of The Hellenic Initiative Australia, and sits on the Governing Council of the Kolling. In 2013, Helen was appointed an Officer of the Order of Australia (AO) in recognition of her distinguished service to public health through leadership in the delivery of improved information and services to cancer patients and their families and contributions to research and clinical trials.

Special responsibilities: Chair, Board; Member, Remuneration & Nominations Committee.



David Krasnostein AM B.Juris LLB LLM

Board member for 16 years

David Krasnostein was former CEO of MLC Private Equity, then Australia's oldest and largest private equity investor. He was former Chief General Counsel of National Australia Bank, Telstra's first General Counsel and Head of Strategic and Corporate Planning, and a Partner of Sidley Austin in Washington DC. David is a Director of The Royal Australian Mint, The Aikenhead Centre for Medical Discovery, the Hellenic Museum of Victoria, the Ear Science Institute and Chairman of Quintessential Equity. In 2019, David was awarded a Member of the Order of Australia (AM) for his significant service to the law through equitable access to justice.

Special responsibilities: Member, Audit, Risk, and Investment Committee; Member, Remuneration & Nominations Committee.



Deeta Colvin (McGeoch) BA

Board member for 12 years

Deeta Colvin (McGeoch) has fulfilled the role of Corporate Relations and Corporate Communications for the Michael Cassel Group since 2016. Prior to this, she provided marketing and special event consulting to CPH and was the Director of Corporate Relations and Events for PBL Media, which included events for Channel 9 and ACP magazines. In 2000, Deeta sold the company she had founded and operated, Colvin Communications International, that specialised in corporate communications and brand marketing. She has held past Board and Committee roles with UNICEF, National Art School, Art Gallery of NSW, Australian Opera, Chris O'Brien Lifehouse, and The Gold Dinner, and is a current Board member of the Queens Club. Deeta was awarded an 'Ordre national du Mérite' by the French Government in 2001 for her contribution to fostering business between France and Australia.

GOVERNANCE (CONTINUED)



Winsome Hall OAM BA

Board member for 9 years

Winsome Hall is a non-executive Director with more than 25 years' experience. She is currently a Director of the NSW Nature Conservation Council and Brandon BioCatalyst, and has held past Director roles in financial planning, consumer protection, infrastructure and venture capital and superannuation funds. Winsome chaired the Sydney Mothers' Day Classic Committee for 8 years, a fun run/walk fundraiser which donates all funds to NBCF, held senior roles in the Commonwealth Public Service, and was ACT Branch Secretary of the Community and Public Sector Union. In 2023, Winsome was awarded the Medal of the Order of Australia (OAM) for her service to the community and for her work with community organisations.

Special responsibilities: Member, Audit, Risk, and Investment Committee.



Megan Keleher BCom MBA GAICD

Board member for 7 years

Megan Keleher has over 25 years of business management and strategic marketing experience across finance, technology, media and telecommunications. Most recently Deputy Chief Executive Officer of Great Southern Bank, she has held executive positions at Fujitsu, Telstra, Foxtel and the Commonwealth Bank of Australia, and also managed her own successful consulting business, specialising in brand strategy and marketing. Megan has significant experience of leading major business transformation, including the award-winning rebranding of Credit Union Australia to Great Southern Bank, culture and capability programs at Telstra and digital change at Foxtel. Megan has previously served as a Non-Executive Director of the Australian Association of National Advertisers, and is currently a member of the Griffith Business School Strategic Advisory Board.

Special responsibilities: Chair, Remuneration and Nominations Committee.



Jenny Fagg B Econ (Honors) PhD GAICD

Board member for 5 years

Doctor Jenny Fagg is an experienced non-executive director and CEO who has led large financial services businesses globally. Currently, she is a Director of Ingenia Communities, PayPal Australia and Mercer Superannuation Australia. Recently, Jenny was the Co-founder and CEO of a fintech company. Prior to this, her roles included: CEO of ANZ National Bank Limited, New Zealand's largest bank; Chief Risk Officer of AMP Group; and EVP of Products and Payments at CIBC (Canada). Jenny also held senior leadership roles at Citibank and KPMG. Her doctoral research was in risk management. A member of Chief Executive Women, Jenny has pioneered financial literacy and diversity in leadership initiatives throughout her career.

Special responsibilities: Chair, Audit, Risk, and Investment Committee.



Professor Grant McArthur AO MB BS FRACP PhD FAHMS

Board member for 3 years

Professor Grant McArthur is a Medical Oncologist, Fellow of the Royal Australasian College of Physicians and holds a PhD in Medical Biology. He is the Executive Director of the VCCC Alliance, inaugural Lorenzo Galli Chair of Melanoma and Skin Cancers at the University of Melbourne, Head, Molecular Oncology Laboratory and Senior Consultant Medical Oncologist at the Peter MacCallum Cancer Centre, along with an Associate Editor role for the Journal of Clinical Oncology. Grant was the inaugural winner of the Translational Research Award of the Foundation Nelia et Amadeo Barletta, held the Sir Edward Dunlop Clinical Cancer Research Fellowship of the Cancer Council of Victoria, won the inaugural Martin Lackmann medal for translational research, received the Medical Oncology Group of Australia, Novartis Oncology Cancer Achievement Award, and has been the recipient of the prestigious Tom Reeve Award from the Clinical Oncology Society of Australia. He is the national and international study co-chair of a number of clinical trials of targeted therapies and has published over 350 papers, including senior or first author publications in many leading global medical journals. In 2023, Grant was awarded an Officer of the Order of Australia (AO) in recognition of his distinguished service to medicine as a clinician scientist through melanoma and cancer research, and through his leadership roles.

Special responsibilities: Co-Chair, Research Advisory Committee



Penny Stragalinos BCom EMBA FCA

Board member for 1.5 years

Penny is a KPMG audit partner, with 30 years' experience as an external auditor, accounting and risk advisor, specialising in the energy and natural resources and industrial markets industries. Penny also has significant transaction services experience, including acquisition, debt raising and share issue due diligence assignments.

Penny was previously the COO of KPMG Australia's Audit, Assurance and Risk Consulting Practice, a director and Chair of the Audit, Risk and Compliance Committee of Victorian Opera, and member of the Audit Committee for The Committee for Economic Development of Australia. Penny is currently on the board of Chartered Accountants Australia and New Zealand (CAANZ) and a member of the Audit and Risk Committee. Penny is a Chartered Accountant, holds a Bachelor of Commerce from The University of Melbourne and an Executive MBA from École Nationale des Ponts et Chaussées School of International Management and The University of Edinburgh.

Special responsibilities: Member, Audit, Risk, and Investment Committee



Professor Maria Kavallaris AM FAHMS FRSN

Board member for 1 year

Professor Maria Kavallaris is a Founding Director of the Australian Centre for NanoMedicine, UNSW Sydney, and Head of Translational Cancer Nanomedicine at the Children's Cancer Institute. Maria is internationally recognised for her significant contributions to cancer research and the development of nanotechnology-based therapeutics and diagnostics. The impact of her research and contributions has been recognised with receipt of prizes and awards, and include Australian Museum Eureka Prizes in 2007 and 2021, AFR/Westpac 100 Women of Influence, 2017 Premiers Science and Engineering Award for Leadership in Innovation, 2019 Lemberg Medal, and the 2020 NSW Premier's Woman of the Year. Maria served as President of the Australian Society for Medical Research and is a Member of Council of QIMR Berghofer. Recognised by the National Health and Medical Research Council (NHMRC) in 2014 as an Australian 'high achiever' in health and medical research, she contributed to high level policy on government panels including NHMRC and the Medical Research Future Fund. She is a Fellow of a number of societies including the Australian Academy of Health and Medical Sciences and a Fellow of the American Institute for Medical and Biological Engineering. In 2019, Maria was appointed a Member (AM) of the Order of Australia for her significant service to medicine, and to medical research, in the field of childhood and adult cancers.

Special responsibilities: Co-Chair, Research Advisory Committee

THANK YOU TO ALL OUR WONDERFUL SUPPORTERS

With no government funding, we rely 100% on the generosity of the Australian community. Our sincere thanks to all of the individuals and organisations listed below for their support this financial year.

GIVING IN KIND

- Adventure Entertainment
- Bailey Nelson Australia
- Corrs Chambers Westgarth
- David Jones
- Estée Lauder Companies
- Fiskars Australia
- ghd
- Herbert Smith Freehills
- Interflora Australia
- LSKD
- Microsoft
- Mr Roses
- Oroton Group
- Port Phillip Estate
- Rockwear
- Safestyle Australia
- San Pellegrino
- Sperling Enterprises
- Tecala Group
- The Card Network
- The Fullerton Hotel
- The Fullerton, Sydney
- TPG (AAPT)
- Tupperware Australia
- Vorgee

GIVING IN KIND – 30TH ANNIVERSARY GALA

- AFLW
- Ahoy Club
- Aireloom
- Autore Group
- Camilla
- Capella Sydney
- Carla Zampatti
- Charles Curran AC – *Sydney yacht*
- Chef Orazio
- Chris Lucas Restaurant
- Cojo
- Daikin
- David Jones
- Erede
- Estée Lauder Companies
- Georges Antoni
- Gildan
- Globite Luggage
- Grandiflora
- Harry the Hirer
- Harvey Norman
- Lexus
- Melanie Grant
- Merivale
- Mobilia
- Morena
- Mr Roses
- MV Pearl Superyacht
- Oroton
- Pandora
- Patricia Stragalinos and David Krasnostein AM – *Private Villa, Lefkada Greece and ALTIS Marvel Stadium Experience*
- Patrick Johnson
- Paul Bangay
- Penfolds Magill Estate
- PIERQMARQ – *Jordy Kerwick Caravaggio's Roar, 2024*
- Port Phillip Estate
- Provincial Home Living
- Ralph Lauren
- Roll & Hill
- Rosedale Farm
- San Pellegrino
- Scoglio Luxury Villa
- Soneva Jani, Maldives
- Sperling
- Stryda
- Temple and Webster
- The Australian Ballet
- The Fullerton Hotel Sydney
- Thomas Hamel
- Tiffany & Co.
- Tilley & Wills Hotels
- Victor Churchill
- Vogue Living
- Vogue Media
- White Story
- Zimmerman

HIGH VALUE FUNDRAISERS

- Robyn Cameron
- Jensens Group
- The Glen Hotel
- Natalie Phillips
- Julie McKinnery
- Hazeldenes Chicken
- Cactus Jack's Redcliffe
- Bridge Burlesque
- Victoria Ellmore
- Yarn Marketplace
- Anna Blacklock
- Fiorrella Miles
- LA Pilates
- Kay Chaplin
- Whitehaven Coal
- Max Waschka
- Adrienne Gledhill
- Qure Skincare
- Thomas Higginson
- Simone Johnston
- Parkdale Yacht Club
- Sydney Portugal Community Club
- Lindt & Sprüngli
- Emanuel Koutsourais
- Barwon Valley Golf Club
- Jayne Roodhouse
- John Stacey
- Grant Whitechurch
- Logan Wagener
- Lauren Falconer
- Burleigh in Pink Committee
- Alisha Henderson
- The Tasmanian Racing Club Inc
- Tracey Horton
- Charlie Leysen
- Bellarine Women's Network
- BFT Gledswood Hills
- Nick Bolton
- Jaimee Abrahams
- Michaela Sargeant
- Courtney Fiebig
- Hockey ACT
- Grace Malouf
- Tweed Valley Equestrian Group
- Simon Kirk
- West Moreton Anglican College P&F

GIFTS IN WILLS

- Estate of the Late Gwen Andersen
- Estate of the Late Steve Peck
- Estate of the Late William (Ric) Finighan
- Estate of the Late Veronica Felberman

Our thanks also go to the 27 Bequest donors who have chosen to remain anonymous. We are honoured to receive your gift.

IN MEMORY

We are extremely grateful to the 49 families and friends who have generously created a NBCF Tribute tree in memory of their loved ones. When someone you love becomes a memory, that memory becomes a treasure.

CIRCLE OF GIVING

- Shadda Abercrombie
- Sanchia Brahim
- Pixie Cohen
- Chrissy Comino
- Charles Curran AC in memory of Eva Curran
- Ciara Griffiths in memory of Grant Griffiths
- Peter Doherty and Jan Swinhoe
- Jaclyn Gazal
- Sarah Ingham
- Sonia Kent
- Jane Kiel
- Larissa Malouf
- Andrea John Moss
- Sue Rose

MAJOR DONORS

- Anne Neate
- Barry Markey in memory of Jocelyne Markey
- Bruce & Joy Reid Trust
- Hamid Daghighi
- Jane Rich
- Jane Wilson
- Jennifer Smith
- Jim Cooper in loving memory of Eva Schuyler Diane
- Kerrie Claffey in loving memory of Tom
- Patagorang Foundation
- Reinfried and Belinda Otter
- Ronald Kaiser and Louise Hassin
- Sally Levy & Zachary Murray
- The Ainsworth Foundation
- The Lin Huddleston Charitable Foundation
- Warwick Negus

Our sincere thanks also go to all other Major Donors who have chosen to remain anonymous. We are honoured to receive your gift.

OUR PARTNERS MAKE IT POSSIBLE

Pink Diamond



Diamond Partners



Major Partners



Partners



NATIONAL BREAST CANCER FOUNDATION

ABN 37 144 841 707

GPO Box 4126, Sydney NSW 2001

p 1300 737 086 e info@nbcf.org.au w nbcf.org.au



– Kathy (diagnosed 2023)
and her family



**National
Breast Cancer
Foundation**